Navigation Links
Amicus Therapeutics Announces Third Quarter 2008 Financial Results
Date:11/3/2008

apies, Inc. ("Shire"), is engaged in ongoing discussions with the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMEA) and will provide an update by the end of the year. A final decision on the global development strategy will follow the conclusion of the discussions with both agencies. Subject to the outcome of the discussions, the Company expects to initiate Phase 3 development of Amigal in the first half of 2009.

In addition, 23 of the original 26 patients continue to be treated in a voluntary Phase 2 extension study designed to monitor long-term safety and efficacy and to evaluate additional doses and dose regimens. Data from this extension study are expected in Q1 2009 prior to the start of the Phase 3 study.

Gaucher Disease:

Plicera(TM) (isofagomine tartrate) is an investigational, oral therapeutic in Phase 2 development for the treatment of Gaucher disease. As previously disclosed, a 6-month Phase 2 clinical trial of Plicera in patients naive to ERT is ongoing and Amicus expects the results of this study to be available in 2009.

Pompe Disease:

AT2220 (1-deoxynojirimycin HCl) is an investigational, oral therapeutic being developed for the treatment of Pompe disease. As previously disclosed, a Phase 2 clinical trial of AT2220 in adult Pompe patients is ongoing and includes an 11 week treatment period with an optional extension study.

In addition, Amicus is conducting preclinical animal studies to evaluate the effects of administering AT2220 in combination with enzyme replacement therapy. Based on the results of the preclinical work, Amicus will consider initiating a clinical trial of the AT2220-ERT combination treatment in Pompe patients.

Other Chaperone Programs:

Amicus continues to invest in research and development to assess the potential for using pharmacological chaperones to treat a broader range of human genetic diseases beyond lysosomal storage diseases. As part of this
'/>"/>

SOURCE Amicus Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Amicus Therapeutics Announces Third Quarter 2008 Results Release Date
2. Amicus Therapeutics to Present at the 2008 UBS Global Life Sciences Conference
3. Amicus Therapeutics Opens Research Facility in San Diego
4. Amicus Therapeutics to Present at the 2008 BioCentury NewsMakers in the Biotech Industry Conference
5. Amicus Therapeutics Announces Second Quarter 2008 Results Release Date
6. Amicus Therapeutics Announces First Quarter 2008 Financial Results
7. Amicus Therapeutics to Present at the Morgan Stanley Global Healthcare Unplugged Conference
8. Amicus Therapeutics Presents Positive Data from Phase 2 Clinical Trial of Plicera(TM) for Gaucher Disease
9. Amicus Therapeutics to Present at the BIO CEO & Investor Conference 2008
10. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
11. Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... 28, 2014 Research and Markets ... Biology Market 2014-2018" report to their offering. ... term synthetic biology covers the designing and engineering of ... as the redesigning of natural biological systems that provide ... a form of extreme genetic engineering because it not ...
(Date:7/28/2014)... July 28, 2014  David Hardison, Ph.D., vice ... Deloitte , has been elected chairman of the ... a non-profit working to establish common protocols around ... it relates to electronic health records. ... of collaborating with organizations across the research and ...
(Date:7/28/2014)... MO (PRWEB) July 28, 2014 ... and services that bring the power of genomics to ... inaugural Appistry Pipeline Challenge . , Two ... president of the National Center for Genome Resources, and ... Hospitals and Clinics of Kansas City. Rounding out the ...
(Date:7/28/2014)... , July 28, 2014  InterMune, Inc. (NASDAQ: ... release its second quarter 2014 financial results at the ... 2014. A live conference call and webcast will be hosted ... day. Interested investors and others may participate ... +1 212-231-2900 (international), conference ID#21728775. A replay of the webcast ...
Breaking Biology Technology:Global Synthetic Biology Market 2014-2018 2ConvergeHEALTH by Deloitte's David Hardison Named Chairman of the Clinical Data Interchange Standards Consortium 2ConvergeHEALTH by Deloitte's David Hardison Named Chairman of the Clinical Data Interchange Standards Consortium 3Appistry Names Industry Experts from the National Center for Genome Resources and Mercy Children's, Kansas City, to Judge Pipeline Challenge Competition 2InterMune to Release Second Quarter Financial Results on August 6 2
... Thomson Reuters announced today the publication of a white ... in entering the Japanese generic drug market. , ... opportunities and strategies for success," notes that a combination ... aging population and wide-ranging government initiatives to reduce healthcare ...
... ROCKVILLE, Md., Oct. 1 Novavax, Inc. (Nasdaq: ... to the board,s corporate governance, compensation and finance committees, replacing ... member James Tananbaum who is retiring from the board. ... and immunology products companies and joined the Novavax board in ...
... BC, Oct. 1 /PRNewswire-FirstCall/ - avVaa World Health Care ... manufacturer and distributor of nationally branded therapeutic, natural skin ... launching their second test run of Neuroskin(R) Psoriasis Relief ... avVaa World Health Care Products will launch a two ...
Cached Biology Technology:Thomson Reuters Explores the Opportunities and Challenges of Entering the Japanese Generic Drug Market 2Thomson Reuters Explores the Opportunities and Challenges of Entering the Japanese Generic Drug Market 3Novavax Announces Board of Director Changes 2Novavax Announces Board of Director Changes 3avVaa World Health Care Products Inc. Announces Second DRTV Test Week 2avVaa World Health Care Products Inc. Announces Second DRTV Test Week 3
(Date:7/28/2014)... Institute for Biologically Inspired Engineering at Harvard University ... be commercialized by a newly formed private company ... personalized medicine products. The announcement follows ... Technology Development (OTD) and the start-up Emulate Inc., ... human Organs-on-Chips platform. , "This is a ...
(Date:7/27/2014)... the asteroid strike that wiped them out if it ... scientists say. , A fresh study using up-to-date fossil ... build a new narrative of the prehistoric creatures, demise, ... in the few million years before a 10km-wide asteroid ... upheaval. This included extensive volcanic activity, changing sea levels ...
(Date:7/27/2014)... potential for global climate change to cut food supplies. ... the interactions between increasing temperature and air pollution ... , A new study involving researchers at MIT shows ... policymakers need to take both warming and air pollution ... looked in detail at global production of four leading ...
Breaking Biology News(10 mins):Wyss Institute's technology translation engine launches 'Organs-on-Chips' company 2Wyss Institute's technology translation engine launches 'Organs-on-Chips' company 3Dinosaurs fell victim to perfect storm of events, study shows 2Study: Climate change and air pollution will combine to curb food supplies 2Study: Climate change and air pollution will combine to curb food supplies 3
... Compared to European Americans, African Americans are four to five ... of African Americans with kidney failure have an increased risk ... a role in this skewed risk between races. Previous studies ... a role. The APOL1 gene creates a protein that is ...
... SAN FRANCISCO, Oct. 13, 2011 -- The tiny phytoplankton ... outsized role in drawing carbon from the atmosphere and sequestering ... as ocean water becomes warmer and more acidic, according to ... study published this week in the journal Global Change Biology, ...
... is a master builder. Using a bottom-up approach, nature ... materials, like diamonds, silicon and even table salt. In ... upon the type and arrangement of atoms within the ... University scientists has learned how to top nature by ...
Cached Biology News:Better ways to predict kidney disease risk for African Americans 2Better ways to predict kidney disease risk for African Americans 3Researchers explore plankton's shifting role in deep sea carbon storage 2Researchers explore plankton's shifting role in deep sea carbon storage 3Emulating -- and surpassing -- nature 2Emulating -- and surpassing -- nature 3
... toward examining a novel object in the environment.The ... all built around a video camera, frame grabber, ... two fields at once and up to 6 ... and records them, but also allows video replay ...
... Magnetofection technology, SilenceMag is the most ... rapid and easy to use, SilenceMag ... Specifically designed for siRNA delivery, SilenceMag ... low doses of siRNA.,SilenceMag formulation gives ...
... Last innovation from Magnetofection technology, SilenceMag ... system available. Simple, rapid and easy ... and non toxic. Specifically designed for ... silencing at very low doses of ...
... C 4 H 10 O 2 ... PRODUCT SPECIFICATIONS Form: White crystalline powder ... 97% Identity: By IR Melting Point: ... Oxidized DTT: less than or equal ...
Biology Products: